DDInter1608 DDInter150
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences, [FDA label]. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL), however, has now been approved for a variety of conditions [FDA label]. On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab).
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Rituximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) binds {v} (Gene) GSTA2
GSTA2 {u} (Gene) is bound by {v} (Compound) Azathioprine
Rituximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) MCM3
MCM3 {u} (Gene) is downregulated by {v} (Compound) Azathioprine
Rituximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Azathioprine
Rituximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) NUCB2
NUCB2 {u} (Gene) is upregulated by {v} (Compound) Azathioprine
Rituximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zidovudine
Zidovudine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleoside Analog
Nucleoside Analog {u} (Pharmacologic Class) includes {v} (Compound) Azathioprine
Rituximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) upregulates {v} (Gene) TPMT
TPMT {u} (Gene) is bound by {v} (Compound) Azathioprine
Rituximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zidovudine
Zidovudine {u} (Compound) causes {v} (Side Effect) Toxic epidermal necrolysis
Toxic epidermal necrolysis {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Rituximab {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Deferiprone {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Rituximab {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Clozapine {u} (Compound) downregulates {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Azathioprine
Rituximab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Fingolimod {u} (Compound) treats {v} (Disease) multiple sclerosis
multiple sclerosis {u} (Disease) is treated by {v} (Compound) Azathioprine
Rituximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) binds GSTA2 (Gene) and GSTA2 (Gene) is bound by Azathioprine (Compound)
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate (Compound) downregulates MCM3 (Gene) and MCM3 (Gene) is downregulated by Azathioprine (Compound)
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Azathioprine (Compound)
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate (Compound) downregulates NUCB2 (Gene) and NUCB2 (Gene) is upregulated by Azathioprine (Compound)
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) is included by Nucleoside Analog (Pharmacologic Class) and Nucleoside Analog (Pharmacologic Class) includes Azathioprine (Compound)
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) upregulates TPMT (Gene) and TPMT (Gene) is bound by Azathioprine (Compound)
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) causes Toxic epidermal necrolysis (Side Effect) and Toxic epidermal necrolysis (Side Effect) is caused by Azathioprine (Compound)
Rituximab may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Azathioprine (Compound)
Rituximab may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Azathioprine (Compound)
Rituximab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod (Compound) treats multiple sclerosis (Disease) and multiple sclerosis (Disease) is treated by Azathioprine (Compound)